| 前收市價 | 12.90 |
| 開市 | 13.10 |
| 買盤 | 17.10 |
| 賣出價 | 18.55 |
| 拍板 | 87.50 |
| 到期日 | 2025-01-17 |
| 今日波幅 | 12.90 - 13.25 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 46 |
Motley FoolIs Bristol Myers Squibb Stock a Buy?
Does Bristol Myers have the potential to be a market-beating stock?
BenzingaNovo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
On Thursday, 2seventy Bio Inc. (NASDAQ:TSVT) completed the asset purchase agreement with Novo Nordisk A/S (NYSE:NVO). Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy’s in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune cells for autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology. Related: FDA Appr
ZacksInvestors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
